Endogenex
Minneapolis, US · Founded 2017 · 28 employees on LinkedIn · 4 known investors
Find your way into Endogenex
310 people in our graph share verified history with the Endogenex team — schools, employers, funds. One of them is your warm intro.
Ericunlockedknows Melanie Hess · together at University of Phoenix (overlapped)
knows the team · via Endogenex
×2knows the team · via University of Minnesota
×3knows the team · via Duke University - The Fuqua School of Business
×5knows the team · via University of Phoenix
Endogenex is a clinical-stage medical device company developing the pulsENDO system, which applies non-thermal pulsed electric field to reset the body's metabolic signaling and improve function in people with type 2 diabetes. Developed in partnership with Mayo Clinic, the therapy aims to help patients manage blood glucose levels and slow disease progression.
Founders & leadership
SP
Stacey PughinLeadership (CEO)
CS
Chris Sorli, MD, PhDinChief Medical Officer
KW
Krissy WrightinChief Financial OfficerKrissy Wright is Chief Financial Officer at Endogenex, a clinical-stage medical device company developing a non-thermal pulsed electric field therapy for type 2 diabetes. She has spent the past two years at Endogenex and brings experience in capital strategy, multi-functional operations leadership, and scaling companies toward commercial readiness.
LC
Lian Cunningham, MD, PhDinVP Clinical Affairs
MH
Melanie HessinRegulatory Affairs LeadershipVice President at Endogenex focused on regulatory affairs and compliance strategy. Hess brings experience in regulatory submission strategy, quality systems, and healthcare operations across multiple device classifications.
MC
Matt CambronneinTechnical/Engineering Leadership
BK
Barham K. Abu DayyehCo-inventor, pulsENDO system
Investors · 4
Funding
SEC filings, press & company announcements$50M disclosed across 1 of 3 rounds · 2024–2026
Source: company announcements and press reports — follow each round's link for the claim.
Competitors · 4
by search overlapBioworld9 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Orogentx8 shared keywordsOrogen Therapeutics uses AI and machine learning to accelerate drug discovery, focusing on small molecule candidates for immuno-inflammatory diseases. The company combines computational chemistry, DNA-encoded library technology, and medicinal expertise to develop novel therapeutic medicines.
Phigenix7 shared keywordsPhigenix develops personalized medicine for cancer, including companion diagnostics and targeted therapies for prostate and breast cancer patients. Its work centers on early detection and targeted inhibition of PAX2 and EN2 oncogenes and a cancer vaccine using Human Beta Defensin-1 (DEFB1) mRNA to direct the immune system against cancer cells.
argenx7 shared keywordsThe company develops therapies for people with severe autoimmune diseases.
Companies competing with Endogenex for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Endogenex do?
- Endogenex is a clinical-stage medical device company developing the pulsENDO system, which applies non-thermal pulsed electric field to reset the body's metabolic signaling and improve function in people with type 2 diabetes. Developed in partnership with Mayo Clinic, the therapy aims to help patients manage blood glucose levels and slow disease progression.
- Who are Endogenex's investors?
- Endogenex's investors include Arboretum Ventures, Intuitive Ventures, Longitude Capital, Lumira Ventures.
- How much funding has Endogenex raised?
- Endogenex has disclosed $50M raised across 1 of its 3 known rounds.
- Where is Endogenex headquartered?
- Endogenex is headquartered in Minneapolis, US.